{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epirubicin+hydrochloride",
    "query": {
      "intervention": "Epirubicin hydrochloride"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 79,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epirubicin+hydrochloride&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T00:40:41.757Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01624441",
      "title": "Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Male Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Recurrent Breast Carcinoma",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dinaciclib",
          "type": "DRUG"
        },
        {
          "name": "Epirubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2012-08-21",
      "completion_date": "2013-09-10",
      "has_results": false,
      "last_update_posted_date": "2018-03-30",
      "last_synced_at": "2026-10-01T00:40:41.757Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624441"
    },
    {
      "nct_id": "NCT00218205",
      "title": "A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Epirubicin",
          "type": "DRUG"
        },
        {
          "name": "Estramustine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Department of Veterans Affairs, New Jersey",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 28,
      "start_date": "2002-07",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2005-09-22",
      "last_synced_at": "2026-10-01T00:40:41.757Z",
      "location_count": 1,
      "location_summary": "East Orange, New Jersey",
      "locations": [
        {
          "city": "East Orange",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00218205"
    },
    {
      "nct_id": "NCT03036488",
      "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Epirubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1174,
      "start_date": "2017-03-07",
      "completion_date": "2025-10-14",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-01T00:40:41.757Z",
      "location_count": 47,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03036488"
    },
    {
      "nct_id": "NCT02788201",
      "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Bladder Cancer",
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "75 approved agents",
          "type": "DRUG"
        },
        {
          "name": "COXEN",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2017-03-27",
      "completion_date": "2019-10-23",
      "has_results": true,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-10-01T00:40:41.757Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788201"
    },
    {
      "nct_id": "NCT00021047",
      "title": "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Extrahepatic Bile Duct Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Liver Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "epirubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-07",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-10-01T00:40:41.757Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Portsmouth, Virginia",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Portsmouth",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00021047"
    },
    {
      "nct_id": "NCT00038402",
      "title": "Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Herceptin",
          "type": "DRUG"
        },
        {
          "name": "Taxol",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Cytoxan",
          "type": "DRUG"
        },
        {
          "name": "Epirubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 74,
      "start_date": "2001-04",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2012-07-20",
      "last_synced_at": "2026-10-01T00:40:41.757Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00038402"
    },
    {
      "nct_id": "NCT00198172",
      "title": "Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Cisplatin plus Epirubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2000-10",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2014-06-03",
      "last_synced_at": "2026-10-01T00:40:41.757Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00198172"
    },
    {
      "nct_id": "NCT01010854",
      "title": "Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "VPA FEC100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2008-12-10",
      "completion_date": "2011-07-29",
      "has_results": true,
      "last_update_posted_date": "2018-03-09",
      "last_synced_at": "2026-10-01T00:40:41.757Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01010854"
    },
    {
      "nct_id": "NCT06829199",
      "title": "A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Early Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin (hydrochloride)",
          "type": "DRUG"
        },
        {
          "name": "Boserolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Epirubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Olaparib (if approved/available locally)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-03-26",
      "completion_date": "2031-03-18",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-10-01T00:40:41.757Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06829199"
    },
    {
      "nct_id": "NCT01204801",
      "title": "Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Focused Microwave Thermotherapy",
          "type": "DEVICE"
        },
        {
          "name": "Chemotherapy (control)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Medifocus, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 238,
      "start_date": "2010-11",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2015-09-24",
      "last_synced_at": "2026-10-01T00:40:41.757Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204801"
    }
  ]
}